SERPINE1 and empyema: Low‐dose, local PAI‐1‐TFT allows a significant decrease in the effective therapeutic dose of the drug, minimizing the risk of bleeding complications, and, thereby, expanding the population of patients with empyema that could tolerate pharmacological treatment.